Dupilumab-associated head and neck dermatitis: Rapid response with abrocitinib treatment.

Development or exacerbation of head and neck dermatitis (HN-D) in association with dupilumab has been reported. Severity of HN-D varies, and may persist even with discontinuation of dupilumab. Development or exacerbation of HN-D is not yet completely understood, and various hypotheses have been made about the possible underlying pathophysiology. To date, there is no established treatment for HN-D in association with dupilumab. We report 2 cases of HN-D occurring following dupilumab treatment, with significant improvement of HN-D following treatment with abrocitinib.